During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Thirty-nine percent of millennials and 35% of Gen Z say access to weight loss drugs would improve their job satisfaction or ...

Academic science is fertilizer of the economy. It creates soil where innovation thrive. Some who don’t know about how things ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric ...

Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...